NCT06400173

Brief Summary

The Montreal Cognitive Assessment (MoCA) is a screening test for detecting cognitive impairment that assesses several cognitive domains (attention and concentration, arithmetic and orientation, memory, etc.). The instructions as well as some test items of the MoCA are presented auditory (spoken). Consequently, performance on the MoCA may be co-dependent on hearing. Therefore, to rule out the possible negative influence of hearing loss on performance on the MoCA, a MoCA for individuals with hearing loss was recently developed. More specifically, the original MoCA was modified by providing the instructions audiovisually (spoken with visual support) as well as by replacing hearing-dependent items. Since replacing items may affect sensitivity and specificity, the MoCA for persons with hearing loss should be revalidated.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

April 12, 2024

Completed
24 days until next milestone

First Posted

Study publicly available on registry

May 6, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

May 6, 2024

Status Verified

May 1, 2024

Enrollment Period

2.3 years

First QC Date

April 12, 2024

Last Update Submit

May 1, 2024

Conditions

Keywords

Cognitive screeningMontreal Cognitive Assessment

Outcome Measures

Primary Outcomes (3)

  • Hearing status

    Based on the results of the tympanometry and pure-tone audiometry the hearing status of the participant will be classified as normal or abnormal. In case of abnormal hearing, the type and severity will be specified.

    This parameter will be assessed once during the first study visit of the patient. Test duration is approximately 20 minutes.

  • MoCA-HI

    The result (max 30) on the MoCA-HI will be calculated.

    This parameter will be assessed once (during the first study visit) or twice (during the second study visit 4 weeks later), depending on the random selection for the test-retest group. Test duration is approximately 15 minutes.

  • Hearing-related quality of life

    Mean scores will be calculated for each subdomain separately (auditory-visual, cognitive, and psychosocial functioning) as well as combined within a total score. The scores can range from 0 to 100 whereby the worse one's hearing-related quality of life, the lower the score.

    This parameter will be assessed once during the first study visit of the patient. Test duration is approximately 15 minutes.

Study Arms (3)

Individuals (>45 years) with mild cognitive impairment and hearing loss

All tests will be administered.

Behavioral: Cognitive screeningBehavioral: Audiological Assessment

Individuals (>45 years) with dementia (Alzheimer, vascular or mixed) and hearing loss

All tests will be administered.

Behavioral: Cognitive screeningBehavioral: Audiological Assessment

Individuals (>45 years) with age-normal cognition and hearing loss

All tests will be administered.

Behavioral: Cognitive screeningBehavioral: Audiological Assessment

Interventions

The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.

Individuals (>45 years) with age-normal cognition and hearing lossIndividuals (>45 years) with dementia (Alzheimer, vascular or mixed) and hearing lossIndividuals (>45 years) with mild cognitive impairment and hearing loss

Four audiological tests are included in the audiological assessment 1. Tympanometry to assss the middle ear status 2. Pure-tone audiometry with headphone to evaluate the hearing thresholds 3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise 4. The hAVICOP questionnaire to assess the hearing-related quality of life

Individuals (>45 years) with age-normal cognition and hearing lossIndividuals (>45 years) with dementia (Alzheimer, vascular or mixed) and hearing lossIndividuals (>45 years) with mild cognitive impairment and hearing loss

Eligibility Criteria

Age45 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Individuals with cognitive impairment and/or hearing loss

You may qualify if:

  • Individuals aged 60 years or older
  • Individuals with normal vision (with lenses or glasses if needed)
  • Individuals with age-related hearing loss
  • Dutch-speaking individuals
  • Individuals capable of giving consent to participate in the study themselves
  • Individuals still residing in their own homes

You may not qualify if:

  • (History of) neurological problems (brain tumor, epilepsy, history of stroke, etc.)
  • Use of influencing medication (e.g., Ritalin and antidepressants)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Ghent Hospital

Ghent, East-Flanders, 9000, Belgium

RECRUITING

MeSH Terms

Conditions

DementiaHearing Loss

Interventions

Mental Status and Dementia Tests

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersHearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Neuropsychological TestsPsychological TestsBehavioral Disciplines and Activities

Study Officials

  • Tim Van Langenhove, MD, PhD

    University Hospital, Ghent

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katrien Kestens, PhD

CONTACT

Tim Van Langenhove, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2024

First Posted

May 6, 2024

Study Start

September 1, 2023

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

May 6, 2024

Record last verified: 2024-05

Locations